CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 8-K Event Auditor change
- 424B5 Offering Prospectus
- 8-K Event Agreement ended · Regulation FD disclosure
- DEFA14A Proxy Proxy Materials
- 8-K Event Shareholder vote results
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale
- 4 Open-market buy Director bought 1,000 shares at $0.69 ($688)
- 4 Open-market buy Director bought 334 shares at $0.91 ($304)
- 4 Open-market buy Director bought 2,000 shares at $1.06 ($2,127)
- 8-K Event Material agreement · Delisting notice · Unregistered share sale
- 4 Derivatives Options or other derivatives
- 10-Q Report Quarterly Report
- DEF 14A Proxy Proxy Statement
- 8-K Event Material agreement · Shareholder rights changed · Bylaws or fiscal year change
- NT 10-Q Other NT 10-Q
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Bylaws or fiscal year change
- SC 13D/A Stake Beneficial Ownership Report
- 8-K Event Material agreement · Delisting notice · Unregistered share sale · Bylaws or fiscal year change
- 4 Derivatives Options or other derivatives
Page 7 of 20 · 398 filings